ストックスクリーナーアプリを入手
0.302
7.22%
-0.0235
アフターアワーズ：
.31
0.008
+2.65%
前日終値:
$0.3255
開ける：
$0.3202
24時間の取引高:
2.01M
Relative Volume:
0.27
時価総額：
$44.26M
収益：
$49.09M
当期純損益:
$-52.15M
株価収益率:
-0.4646
EPS:
-0.65
ネットキャッシュフロー:
$-45.93M
1週間 パフォーマンス:
-11.85%
1か月 パフォーマンス:
-43.59%
6か月 パフォーマンス:
-79.03%
1年 パフォーマンス:
-77.63%
1日の値動き範囲:
$0.2906
$0.3262
1週間の範囲:
$0.2906
$0.3699
52週間の値動き範囲:
$0.1718
$2.04
Biodesix Inc Stock (BDSX) Company Profile
BDSX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
0.302 | 50.21M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
402.82 | 148.60B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.90 | 132.07B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
513.36 | 40.34B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.92 | 30.82B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
140.33 | 23.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-26 | 開始されました | Craig Hallum | Buy |
| 2024-05-13 | 開始されました | TD Cowen | Buy |
| 2024-05-03 | 開始されました | Lake Street | Buy |
| 2021-11-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 開始されました | BTIG Research | Buy |
| 2020-11-23 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-23 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-23 | 開始されました | William Blair | Outperform |
すべてを表示
Biodesix Inc (BDSX) 最新ニュース
Scotiabank Has Lowered Expectations for Biodesix (NASDAQ:BDSX) Stock Price - Defense World
Biodesix Announces New Data on the VeriStrat® Test to be Present - GuruFocus
Biodesix to Present New Data on Host Immune Classifier for NSCLC at 2025 ASCO Annual Meeting - Nasdaq
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting - GlobeNewswire
Game-Changing Cancer Test Triples Survival Rate: New Clinical Data Transforms Lung Cancer Treatment - Stock Titan
Independent Director of Biodesix Picks Up 15% More Stock - Yahoo Finance
Biodesix (BDSX) Target Price Reduced to $2 by Scotiabank | BDSX Stock News - GuruFocus
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut - MSN
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut By Stocktwits - Investing.com India
Scotiabank cuts Biodesix stock target to $2, maintains outlook By Investing.com - Investing.com Canada
Biodesix Approves Reverse Stock Split at Annual Meeting - TipRanks
Scotiabank cuts Biodesix stock target to $2, maintains outlook - Investing.com
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX S - GuruFocus
Biodesix (BDSX) Sees Target Price Lowered by Scotiabank | BDSX Stock News - GuruFocus
Biodesix price target lowered to $2 from $3 at Scotiabank - TipRanks
Biodesix to Participate in Upcoming Investor Conferences | BDSX Stock News - GuruFocus
Biodesix to Participate in Upcoming Investor Conferences - GlobeNewswire
Biodesix Executives Set for Major Investor Conferences: William Blair and Craig-Hallum Presentations Ahead - Stock Titan
Director’s Massive Stock Purchase Signals Confidence in Biodesix! - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Biodesix's (BDSX) "Market Perform" Rating Reaffirmed at William Blair - MarketBeat
Craig Hallum Cuts Biodesix (NASDAQ:BDSX) Price Target to $1.50 - Defense World
William Blair Has Bearish Estimate for Biodesix Q2 Earnings - Defense World
Biodesix revises 2025 revenue guidance to $80M–$85M amid sales force reconfiguration and primary care expansion - MSN
Susquehanna International Group LLP Grows Stock Holdings in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
Biodesix, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Biodesix, Inc. (NASDAQ:BDSX) Q1 2025 Earnings Call Transcript - MSN
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers - simplywall.st
Biodesix Announces New Clinical and Economic Data for Its Nodify Lung® Tests At ISPOR and ATS - marketscreener.com
News Flash: 6 Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Earnings Are Under Threat - Yahoo Finance
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS | BDSX Stock News - GuruFocus
Biodesix, Inc. to Present New Data on Lung Cancer Diagnosis and Testing at ISPOR and ATS 2025 Conferences - Nasdaq
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS - GlobeNewswire
New Clinical Data: Biodesix Lung Cancer Tests Could Prevent 60% of Unnecessary Invasive Procedures - Stock Titan
Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award - GlobeNewswire
Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Craig-Hallum Adjusts Price Target for Biodesix (BDSX) | BDSX Sto - GuruFocus
Diagnostic Leader Biodesix Clinches Elite Colorado Workplace Award, Employee Survey Reveals Why - Stock Titan
Biodesix stock plunges as life-sciences firm cuts sales projection - BizWest
Biodesix (BDSX): Analyst Maintains Buy Rating Despite Lowered Pr - GuruFocus
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BD - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating By Investing.com - Investing.com Nigeria
Biodesix stock target cut to $2 by TD Cowen, retains buy rating - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Biodesix (BDSX) Target Price Lowered by Lake Street Analyst | BDSX Stock News - GuruFocus
Biodesix Inc Reports Q1 2025 Earnings: EPS of -$0.08 Misses Esti - GuruFocus
Biodesix stock rating cut to Market Perform at William Blair By Investing.com - Investing.com South Africa
BDSX: Canaccord Genuity Lowers Price Target for Biodesix | BDSX Stock News - GuruFocus
Canaccord cuts Biodesix stock target to $1.50, keeps buy rating - Investing.com Australia
BDSX Reports Q1 Revenue Below Expectations, Highlights Strategic - GuruFocus
Biodesix Inc (BDSX) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
1.71%
大文字化:
|
ボリューム (24 時間):